文献速递老年慢病共病管理老年综合评估

表观遗传年龄加速与90岁女性多重共病负担的前瞻性关联

The Association of Epigenetic Age Acceleration and Multimorbidity at Age 90 in the Women's Health Initiative.
PubMed 文献 · J Gerontol A Biol Sci Med Sci · 2023-01-01

结果显示,AgeAccelPheno每增加1个标准差,90岁时多重共病累积率增加6%(RR=1.06;95%CI=1.01-1.12;p=.025),加权评分增加7%(RR=1.07;95%CI=1.01-1.13;p=.014)。AgeAccelHorvath、AgeAccelHannum和AgeAccelGrim的关联较弱,其中后两者未达统计学显著性。

要点

  • AgeAccelPheno每增1个标准差,90岁多重共病计数风险增6%,加权评分增7%。
  • AgeAccelHannum与AgeAccelGrim的关联较弱且未达统计学显著性。
  • EAA或可作为长寿女性晚年多重共病负担的生物标志物预测指标。

核心结论

  • AgeAccelPheno和AgeAccelHannum可能预测老年女性90岁时的多重共病计数和加权评分,或可作为晚年多重共病负担的生物标志物预测指标。

研究设计与样本

  • 基线估计Horvath泛组织、Hannum、PhenoAge和GrimAge四种表观遗传年龄加速(EAA)指标。
  • 多重共病计数包含12种慢性病,加权评分基于每种疾病与研究人群死亡率的关联进行加权。
  • 采用混合效应泊松回归和线性回归模型,并纳入与EAA和多重共病均相关的基线协变量,估计相对风险(RR)和95%置信区间(CI)。

主要发现

  • 对于存活至90岁的女性,AgeAccelPheno每增加1个标准差,多重共病累积率增加6%(RR=1.06;95%CI=1.01-1.12;p=.025)。
  • AgeAccelPheno每增加1个标准差,加权多重共病评分增加7%(RR=1.07;95%CI=1.01-1.13;p=.014)。
  • AgeAccelHorvath、AgeAccelHannum和AgeAccelGrim每增加1个标准差的关联弱于AgeAccelPheno,其中后两者未达统计学显著性。

临床怎么用

  • 在老年女性中,可考虑检测AgeAccelPheno以辅助识别90岁时多重共病负担较高的个体。
  • AgeAccelHannum也可作为候选预测指标,但AgeAccelGrim的预测价值有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Epigenetic age acceleration (EAA), a measure of accelerated biological aging, has been associated with an increased risk of several age-related chronic conditions. This is the first study to prospectively examine the relationship between EAA and both multimorbidity count and a weighted multimorbidity score among long-lived postmenopausal women. METHODS: We included 1 951 women from the Women's Health Initiative who could have survived to age 90. EAA was estimated using the Horvath pan-tissue, Hannum, PhenoAge, and GrimAge "clocks." Twelve chronic conditions were included in the multimorbidity count. The multimorbidity score was weighted for each morbidity's relationship with mortality in the study population. Using mixed-effects Poisson and linear regression models that included baseline covariates associated with both EAA and multimorbidity, we estimated relative risks (RRs) and 95% confidence intervals (CIs) for the relationships between each EAA measure at the study baseline with both multimorbidity count and weighted multimorbidity score at age 90, respectively. RESULTS: For every one standard deviation increase in AgeAccelPheno, the rate of multimorbidity accumulation increased 6% (RR = 1.06; 95% CI = 1.01-1.12; p = .025) and the multimorbidity score by 7% (RR = 1.07; 95% CI = 1.01-1.13; p = .014) for women who survived to age 90. The results for a one standard deviation increase in AgeAccelHorvath, AgeAccelHannum, and AgeAccelGrim with multimorbidity accumulation and score were weaker compared to AgeAccelPheno, and the latter 2 did not reach statistical significance. CONCLUSION: AgeAccelPheno and AgeAccelHannum may predict multimorbidity count and score at age 90 in older women and, thus, may be useful as a biomarker predictor of multimorbidity burden in the last decades of life.

来源:J Gerontol A Biol Sci Med Sci,查看原文。版权归原作者所有。

引用

  1. Jain P, Binder A, Chen B, et al. The Association of Epigenetic Age Acceleration and Multimorbidity at Age 90 in the Women's Health Initiative. J Gerontol A Biol Sci Med Sci. 2023. PMID: 36107798. doi:10.1093/gerona/glac190

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。